This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.
The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Sign up for our daily news round-up!
The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.
The study, which is expected to produce initial results in the first half of 2027, will support potential approval in the US and Europe. By GlobalData Learn more about Strategic Intelligence RemeGen is conducting a global Phase III clinical trial with telitacicept for the treatment of generalised myasthenia gravis.
Then, we will need to run pre-clinical trials of these crystals, which will be in 2026 or 2027. Then the next step is to produce meaningful quantities of these crystals, which will be next year.” After that, it will be about compliance and regulation, as we must ensure that all our processes adhere to pharma regulations.
Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard.
Member states of the organisation agreed earlier this year to pay 20% more in membership fees to stopgap the US funding shortfall, though WHO’s overall budget for 2026-2027 will be lower than that for 2024-2025. How will RFK Jr’s American dream for vaccines play out? Sign up for our daily news round-up!
With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. How will RFK Jr’s American dream for vaccines play out? As of December 2024, the company reported cash reserves of $85.2m.
Communication between European Union (EU) member states is ongoing to finalise the details of the legislation, but at its core, the EHDS will provide a single registry of patient data from across the continent. Trust is something that you earn, so how we communicate what’s coming out of this directive is very important.
from 2022 to 2027. Though South Korea is the third largest biopharma innovation hub, Suyoung admits that local pharma companies have low HCP engagement rates because marketers still use traditional methods of communication such as email, phone calls, and face-to-face visits. And it makes sense.
4 The biopharmaceutical industry is taking steps to increase its environmental sustainability, 5 which begins with identifying and testing alternatives to existing procurement, materials, logistics, equipment, services, manufacturing processes, packaging, and facility design 6 (see Table 1). A Strategy for the Sector 2023–2027.”
4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). Nature Communications 12, no. Biotechnology Progress 36, no. 3 (2020):e2970.
The cases covered the same types of contaminants and impurities noted in Table 1: microbial contaminants, process-related im-purities, metal contaminants, packaging-related contaminants, drug cross-contamination, and an “unknown” category encompassing other contaminants associated with the manufacturing process, including those from cell culturing.
Texas Goes BIG on Food Warnings Beginning on January 1, 2027, Texans may notice new warning labels on some food products sold in their fair state. This labeling requirement will apply to packages “developed or copyrighted” from January 1, 2027 onward. Here’s what industry needs to know. What Made the List? Synthetic dyes.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content